Multiple sclerosis (MS) is a lifelong neurologic disease affecting the central nervous system and resulting in demyelination and axonal loss over time. Symptoms are widely variable and often involve motor and sensory impairment, vision loss, gait disturbance, cognitive dysfunction, and fatigue. Furthermore, MS is a disease common to women of childbearing age, with 70% of patients being women and with 90% of patients presenting between the ages of 15 and 50.
Similarly, accurate knowledge about environmental and genetic influences on MS is crucial for informed family planning considerations. Overall, MS is not considered a principally hereditary illness, and the risk for MS in the general population is approximately 0.1% compared with the risk in children of an affected parent, which is approximately 3%. For dizygotic twins, the risk for the second twin developing MS is about 4%, and for monozygotic twins the risk is about 30% over their lifetime. 7, 8 In terms of environmental risks, there was previous concern over use of oral contraceptives, which has been dispelled by studies showing both no effect and even possible association with a milder MS course. It is also important that women with MS and their offspring are not dissuaded from using oral contraceptives over concerns of developing MS. 9, 10 Furthermore, familiarity with pregnancy risks with MS disease-modifying therapies (DMTs) can lead to safe family planning practices. Current safety data is only based on animal studies and/or human observational cohorts and registries. Of the 13 approved medications, glatiramer acetate has shown no evidence to date of any danger to fetuses, but there is possible evidence for toxic effects with the other medications in animal and/or human studies, including known harm with teriflunomide in animal studies for which there is an absolute contraindication during pregnancy.
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Patients on certain DMTs must be aware that they might need to undergo a washout period prior to becoming pregnant. Moreover, it is equally important for women to know that it is safe to receive intravenous methylprednisolone (IVMP) for treatment of MS exacerbations during the second and third trimesters, and with caution during the first trimester.
For breastfeeding women it is recommended to "pump and dump" for four hours after IVMP treatment. 1, 5, 12 Use of DMTs then necessitates education about consistent contraception and safety while breastfeeding. For example, while there is no evidence that glatiramer acetate is absorbed into a newborn's gastrointestinal tract to any significant degree, safety has not been established. There was one study of interferons and breast milk that showed that it is present in extremely small amounts, 13 and natalizumab is detectable in breast milk but might not be absorbed by an infant. All three oral MS medications (fingolimod, dimethyl fumarate, teriflunomide) are known to be detectable in animal breast milk. 11 In terms of relapse risk, the decision to breastfeed versus restarting MS therapy after delivery is complex, as patients must weigh increased risk for postpartum relapse off of therapy with the putative protective benefits of breastfeeding. However, exclusive breastfeeding typically requires a patient to remain off of DMTs, and thus the risks and benefits of these highly personal decisions must be made on an individual basis.
14 Given these complexities, our objective was to delineate which misconceptions might exist within the female MS population with regards to family planning, pregnancy, breastfeeding, MS genetics, and medication safety through a pilot study.
Methods
A questionnaire with topics pertaining to MS and pregnancy was created by three neurologists, two of whom are MS specialists. The questions ranged from simple to more esoteric with the intention of determining the full spectrum of patient knowledge. The questionnaire was first reviewed for content and appropriateness by an interdisciplinary team at the MS center. Questionnaires were then distributed to patients who were willing to participate and finished anonymously. Upon completion the participants were given an educational answer key. The project was reviewed by the Institutional Review Board and deemed exempt.
We recruited all willing patients who met our inclusion criteria seen at the MS center every clinic day during a 2-month time window. Thirty-seven female patients of childbearing age (which, for the purposes of the study, was defined as ages 18 to 50) with confirmed MS or clinically isolated syndrome (CIS) were selected to participate from a single MS center in New York City. All types of MS were included but only patients with relapsing remitting, secondary progressive, and clinically isolated syndrome participated (see Table 1 ). No patients with primary progressive MS completed the survey. The status of being on a DMT at the time of the study was not a basis for exclusion. Ability to speak and read English was also an inclusion criterion.
Baseline demographics and reproductive history were collected and included the following: number of years since MS diagnosis, number of pregnancies before and after MS diagnosis (including terminations or miscarriages), type of MS, the number of total adverse events during pregnancy, consistent use of birth control while on a DMT, and patients' primary source of MS information (including their MS care provider, patient care organizations, and the Internet).
The knowledge-based questionnaire (see Figure 1 ) comprised 22 questions divided into four main categories: 1) the effect of pregnancy on MS; 2) the effect of MS on pregnancy; 3) medication safety during pregnancy and breastfeeding; and 4) the effect of MS on offspring. Patients were given an educational answer key after completing the questionnaire.
Using Excel © and Stata © data analysis and statistical software, the frequency of answers in the demographic section was calculated to provide a mean with standard deviation and a range. The number of correct answers was also calculated and reported as frequency and How strongly do you agree or disagree with the following statements?
12) Pregnancy is associated with a decrease in the number of MS exacerbations, particularly in the third trimester.
☐ agree ☐ disagree ☐ don't know 13) Interferon beta-1a and -1b are the safest MS medications to use during pregnancy.
The rates of infertility in women with MS are marginally higher than in the general population.
☐ agree ☐ disagree ☐ don't know 15) Endocrine drugs used when someone is trying to become pregnant using in-vitro fertilization are safe in MS and have not been associated with an increased number of exacerbations.
☐ agree ☐ disagree ☐ don't know 16) Most MS immunosuppressive medications are safe to use while breastfeeding.
17) The disease process of MS is linked to a moderately higher rate of congenital malformations.
☐ agree ☐ disagree ☐ don't know 18) If a woman with MS has a daughter, that daughter will have about a 10 percent chance of developing MS over the course of her lifetime.
19) The risk of having an MS relapse in the postpartum period (the time after delivery of baby) is nearly doubled in the first 3 months after delivery.
20) The frequency of urinary tract infections during pregnancy is higher in women with MS than in women without MS.
21) The general recommendation for women taking MS disease-modifying drugs is that the drug be stopped at least 12 months prior to conception and that two forms of birth control be used in the meantime.
☐ agree ☐ disagree ☐ don't know 22) In general, when the FDA says a medication is Category C during pregnancy, this means that it is safe to take during pregnancy because it only showed bad outcomes for fetuses of lab animals, not humans.
23) The more pregnancies a woman with relapsing remitting MS has, the lower her risk of reaching an Expanded Disability Status Scale (EDSS) of 6.0, a score which correlates to requiring some sort of ambulation device assistance, such as cane, walker, wheelchair.
☐ agree ☐ disagree ☐ don't know 24) Studies have shown that using intravenous immunoglobulin (IVIg) for the first three months after delivery can decrease the risk of a relapse in that period.
☐ agree ☐ disagree ☐ don't know 25) If a woman with MS has a flare while pregnant, she will not be able to receive intravenous steroids as she would if she were not pregnant.
26) It is true that oral MS medication teriflunomide (Aubagio ® ) is considered category X in pregnancy, meaning that there is positive evidence of serious fetal abnormalities in animals, humans, or both.
27) There is a marginal increase in the rate of caesarian section in women with MS compared to the general population.
☐ agree ☐ disagree ☐ don't know 28) Since breastfeeding can delay the return of relapses post-partum, all women are advised to breastfeed after delivery as opposed to restarting diseasemodifying drugs.
☐ agree ☐ disagree ☐ don't know 29) A woman with MS on interferon beta-1a wants to become pregnant, but her MRI brain shows multiple new contrast-enhancing MS lesions, which are a marker of active disease. She is asymptomatic. It is still advisable for her still to go ahead with attempts to become pregnant.
30) It is very important that women with MS who take disease modifying drugs use birth control until they are ready to plan a pregnancy, as there is an increased risk of fetal abnormalities and spontaneous miscarriage with most of these drugs.
31) The risk of intrauterine fetal growth restriction (smaller weight and length of baby) is much higher in women with MS.
☐ agree ☐ disagree ☐ don't know 32) A 28-year old woman with MS has some residual weakness and spasticity in her legs from an attack two years prior which requires her to use a cane. Since then, she has not had any new symptoms. She becomes pregnant and is told that she will definitely require a caesarian section. How much do you agree with this assessment?
☐ agree ☐ disagree ☐ don't know 33) Use of oral contraceptive pills has been implicated as a possible risk factor for the development of MS. 
Results
The average age of patients surveyed was 36 (range 23-47 years). The mean age at the time of MS diagnosis was 30. The average number of years since MS diagnosis was 6.7. Eleven patients had been pregnant after MS diagnosis, 30.6%, and nine patients had been pregnant prior to diagnosis, 24.3% (see Table 2 ). Of those who had been pregnant at any time, 8% (n=3) reported an adverse fetal outcome when pregnant;
however, reasons for the adverse outcomes were not provided. In terms of where patients reported obtaining information about their disease, 78%
reported that their MS care provider was their main source of information.
Patients answered an average of 32.8% (standard deviation [SD]±20.3) of questions correctly overall. In the subgroup of patients who had been pregnant since their MS diagnosis, there was a slightly higher average score of 40.5% (SD±24.7) correct. Those who had not been pregnant since diagnosis overall had an average of 31.3% (SD±17.9) correct. However, the difference in test scores between the groups was not statistically significant, p-value 0.21.
The four main categories of knowledge were analyzed for correctness, and the largest area of deficit pertained to the effect of MS on reproduction, with an average of 27.7 percent (SD±10.1) of questions answered correctly (see Table 3 ). When patients who had been pregnant after MS diagnosis were compared with those who had not been pregnant, answering 32.0% reported that they did not consistently use some form of birth control.
Concurrently, over half of responders, 51.5%, knew that oral contraceptives do not carry an increased risk for development of MS.
Questions pertaining to the effect of MS on offspring yielded the highest subcategory score with 41.2 (SD±34.9) answering correctly. Only on these questions did patients who had not been pregnant since MS diagnosis score overall higher than women who had been pregnant, 41.7% (SD±35. 
Discussion
This pilot in essence reveals both limitations in patients' knowledge and also serves as a "difficulty validation" on our survey instrument, as the questions were both clinically relevant and challenging to the correct degree. Using this questionnaire, we found that the majority of our population of female MS patients of childbearing years did not have a sufficient understanding of many topics pertinent to reproduction. We identified a number of misconceptions related to significant reproductive topics, medication safety, and patient behavior in women with MS.
An area of relatively robust knowledge was the effect of MS on offspring.
Large knowledge gaps were found, however, in the areas of disease effect on reproduction and medication safety during pregnancy and breastfeeding.
Of particular concern was a low awareness of the need for birth control while on DMTs, with a concurrently low self-reported claim of effective use of contraception. Over half of responders knew that oral contraceptives do not cause MS, making the low use of birth control less likely to be attributable to a fear of its use. Furthermore, answers to questions about US Food and Drug Administration (FDA) safety categories reflected a poor understanding of this classification system. Education on the topic of pregnancy safety categories for DMTs could help to prevent adverse fetal outcomes. However, it is important to note that over the course of this study, there has been a plan to phase out the current FDA classifications and replace them with a more descriptive labeling system. 16 Any future large cohort study will have to addend the questionnaire accordingly.
Knowledge gaps pertaining to the possibility of relapse treatment during pregnancy could lead to undertreatment of disease activity occurring during pregnancy. It is notable that patients who had previously been pregnant had a trend toward scoring better on this question, suggesting that this health knowledge was acquired during pregnancy when it was most applicable. However, overall comparison of patients who had been pregnant since diagnosis to those had not been pregnant did not ultimately show statistically significant differences in scores.
Our study also identified patients' misperceptions about negative effects of MS on pregnancy and offspring, which might discourage them from starting families. While some studies have shown a higher rate of assisted vaginal deliveries, for example requiring induction and slower progression of labor, 5 there is evidence to suggest that mothers and newborns do equally well and do not have longer birth hospitalizations that non-MS counterparts, even when accounting for longer disease duration and increased disability. 15 Our study has several limitations. As a single-center pilot study conducted in an urban area, our results might not be broadly generalizable to the MS population. An alternative explanation for the poor knowledge-based scores was that the questions were too difficult, rather than reflecting a genuine lack of reproductive education in this population. It should be noted that the population served by this MS center is a comparatively highly educated and health-literate group.
Conclusions
Our data identified patient misconceptions on a range of important reproductive topics related to MS. Use of similar knowledge assessments is practical for MS centers in order to identify education needs. Given that the majority of participants indicated that their MS practitioners are their primary source of information, it is critical that providers take the time to educate effectively their patients on issues of reproduction, prior to and after conception. We intend to replicate this study on a broad geographic cohort towards planning educational initiatives to address these needs.
Future research in this area could evaluate the impact of pregnancy-related educational initiatives on improving reproductive health outcomes. ■
